Molecular targeted therapy for hepatocellular carcinoma: Current and future

doi:10.3748/wjg.v19.i37.6144

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 37

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9549)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

552

HTML

6594

Figures (1-2)

259

Tables (1-2)

460

Sum=7865

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

947

Download

737

Sum=1684

Oct 7, 2013 (publication date) through Dec 24, 2024

Times Cited of This Article

Times Cited (63)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Oct 7, 2013; 19(37): 6144-6155
Published online Oct 7, 2013. doi: 10.3748/wjg.v19.i37.6144

Full Size Figure Download Figure

Figure 2 PI3K/Akt/mTOR pathway and the molecular agents targeting this pathway. BAD: BCL-2-associated death promoter; EGF: Epidermal growth factor; EGFR: EGF receptor; IGFR: Insulin-like growth factor (IGF) receptor; mTOR: Mammalian target of rapamycin; PTEN: Phosphatase and tensin homolog; PI3K: Phosphatidylinositol-3-kinase.

Citation: Shin JW, Chung YH. Molecular targeted therapy for hepatocellular carcinoma: Current and future. World J Gastroenterol 2013; 19(37): 6144-6155
URL: https://www.wjgnet.com/1007-9327/full/v19/i37/6144.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i37.6144